Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target […]
More Stories
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
Global Trade in 2026: AI Investment Is Rewriting the Map of World Commerce By Looking Times | November 13, 2026...
The AI Investment Boom: Can Record Spending Deliver Real Productivity?
The AI Investment Boom: Can Record Spending Deliver Real Productivity? By Looking Times | November 13, 2026 Image: Derrick Coetzee,...
Global Trade in 2026: How AI Is Reshaping the World Economy
Global shipping remains a vital link in international trade. Image: Wilfredor, Wikimedia Commons, CC0 1.0 (public domain dedication). Image source...
How to Eliminate Bottlenecks in Cross-Team Workflows
A business is often made of different teams. These teams need to work together. However, things don’t always go as...
Global Economy and International Trade: How the World Is Building a More Connected but Uncertain Future
The global economy is entering a new era of transformation as international trade, technological innovation and geopolitical tensions reshape relationships...
54,000 Bankruptcies Filed in October, Report Says
By Naveen Athrappully A total of 54,028 bankruptcy filings were made in October, a 2 percent jump from a year...